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I M M U N O H E M A T O L O G Y
 
Persistence of cefotetan on red blood cells
 




Cefotetan can cause severe immune 
hemolytic anemia that may persist long after the drug is 
discontinued. To study the binding of cefotetan to RBCs, 
patients who received cefotetan were followed and tested 
for the presence of antibody to cefotetan.
 
STUDY DESIGN AND METHODS:
 
 Patients receiving 
cefotetan were identified from pharmacy and nursing 
records. Blood samples obtained for routine hematology 
tests were analyzed. Cefotetan binding to patients’ RBCs 
was tested using a previously characterized high-titer 
anticefotetan serum by gel technique. To determine the 
minimum amount of drug necessary for binding to occur, 





 Sixty patients receiving 1 to 25 g IV (median, 
2 g) of cefotetan were followed for 1 to 123 days (median, 
18 days). All were initially positive, for cefotetan on RBCs. 
Positivity persisted for up to 98 days after the last dose 
of drug. Fifteen patients became negative during follow-
up. The first negative sample occurred at Day 30 to 123. 
Using the midpoint between the last positive and first 
negative to estimate of the duration of positivity, we 
estimate that cefotetan remains RBC-bound for 16.5 to 
92  days (median, 67.5 days). During the follow-up period, 
five patients developed anticefotetan detectable in the 
serum. Twenty patients receiving other cephalosporin 
antibiotics showed no specific reactivity of their RBCs with 
anticefotetan. In vitro studies showed a minimum 




mol/L at physiologic 
pH, which was not significantly altered by RBC 




 Cefotetan is tightly bound to RBCs 
after intravenous administration and remains detectable 
for weeks after the last dose. Antibodies to cefotetan may 
occur in about 8 percent of patients receiving the drug. 
The minimum necessary concentration for RBC binding 





mol/L from a single IV dose of 1 g.
 
efotetan is a second-generation cephalosporin
with a broad spectrum of activity against Gram-
negative rods. It is commonly used for preoper-
ative prophylaxis before abdominal surgery and
Caesarian section. Like other cephalosporins, cefotetan
can cause immune hemolytic anemia (IHA). Serologic
studies have suggested that cefotetan is the most common




 A review of cefotetan-
induced hemolytic anemia reported to the USFDA and the




 Of these cases, 76
percent were female, 59 percent had received the drug for
surgical prophylaxis, 30 percent received the drug for 1
day or less, and 18 percent had a prior exposure to
cefotetan. Fifteen fatalities were identified. Within the
fatal cases of IHA, the treatment length ranged from 1 to
11 days. Eleven of the fatal cases had no prior history of
exposure to the drug.





 We have previously observed prolonged
hemolysis in cefotetan-induced IHA after withdrawal of









 which is relatively long compared to
other cephalosporins, the persistence of IHA for days or
weeks is unexplained. We hypothesized that cefotetan may
remain bound to RBCs after expected clearance of the drug
from plasma. We have studied the binding of cefotetan to




Inpatients receiving cefotetan at the University of Michi-
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records. When there was any question of dosage, medica-
tion administration records were checked. Blood samples
were obtained after routinely ordered hematology tests
were performed. The Institutional Review Board of the
University of Michigan Medical School approved the study.
Cefotetan-coated cells were prepared, as previously









cefotetan disodium (AstraZeneca, Wilmington, DE) dis-









 Drug-coated RBCs were stored in Alsever’s
solution until used. For detection of cefotetan on RBCs,
we used a previously characterized antibody from a
patient with cefotetan-induced IHA (IgG titer = 250,000).









500 dilution and did not react with uncoated RBCs





 IgG Gel cards (Ortho Clinical Diag-
nostics, Raritan, NJ). For each sample analyzed, RBCs









L was dispensed into each of two gel





















L of 6 percent albumin
were added to the other column as a control for IgG coat-





C, centrifuged, and read according to the
manufacturer’s directions. Cefotetan-coated RBCs were
included in each batch as a positive control, and matched
uncoated RBCs were included as a negative control. When
the albumin control was positive, indicating that the RBCs
had a positive DAT, the patient’s serum was tested neat
against cefotetan-coated RBCs and control RBCs to detect
anticefotetan.
For in-vitro studies, cefotetan disodium was prepared
immediately before use in PBS pH 7.4. Five percent sus-
pensions of normal donor RBCs were prepared in PBS.
Serial twofold dilutions of cefotetan were prepared, taking
into account the RBC diluent volume, with final concen-















C, washed with PBS,








500 dilution by gel
technique as above. Experiments were performed in three
replicates using four different normal donor RBC samples.
In some experiments, RBCs were pretreated with ficin,






Sixty patients receiving cefotetan were identified. All
received intravenous doses of the drug. The total dosage








g). The follow-up time
ranged from 1 to 123 days (median, 18 days).
Twenty patients not receiving cefotetan were also
tested. Seven patients received ceftriaxone, four received
cefazolin, one received ceftazidime, and one received
cefepime. One patient who received ceftriaxone had a
positive test with both anticefotetan and 6-percent albu-
min. This patient had a 1+  positive DAT with anti-IgG,
negative with anti-C3. She had a history of dematomyosi-
tis, rheumatoid arthritis, and chronic HBV infection.
There was no history of cefotetan exposure. An RBC eluate
was not performed. None of the others manifested a pos-
itive test with anticefotetan or 6-percent albumin.
All patients receiving cefotetan manifested a positive
test of 1+ strength or greater with anticefotetan on the first
sample obtained after with drug was begun. Positivity per-
sisted for up to 98 days after the last dose was given (Fig.
1). During the follow-up period, a negative sample was
obtained on 15 patients. The first negative sample
occurred at Day 30 to 123. Using the midpoint between
the last positive and first negative to estimate the duration
of positivity, we estimate that cefotetan remains RBC-
bound for 16.5 to 92 days (median, 67.5 days) (Fig. 2).
During the follow-up period, five patients developed
anticefotetan antibodies detectable in the plasma. Anti-
cefotetan was first detected 5 to 78 days (median, 54 days)
after the first dose. One of these patients had a previous
documented exposure to cefotetan; however, complete
records were not available for all patients. Chart reviews
were performed. No patient had a clinically evident
hemolytic reaction. All five patients had decreases in Hb









g/dL). Serum bilirubin con-
centration was measured in three patients after antice-
fotetan was detected and was normal in all cases.
Antibody titration was performed in one case. The anti-
cefotetan titer was 2560. Three of these patients received















Length of follow-up. The bars represent the length of 
follow-up from the last drug dose for each patient in the study. 
The top of the black bar indicates the last positive sample 
tested, and the top of the white bar indicates the first negative 
sample tested. The length of the white bars indicates the inter-
























CEFOTETAN BINDING TO RBCs
 




apparent difference between antibody producers and
nonantibody producers in the dose of cefotetan adminis-
tered (Fisher’s exact test, p = 0.12).
Eight patients received RBC transfusions during the
follow-up period for which paired pre- and posttransfu-
sion samples were available. The transfusions occurred
from 2 to 66 days after the last drug dose. In seven of these,
there was no change in reactivity strength of the post-
transfusion RBCs with anticefotetan, as compared to a
pretransfusion sample. With one transfusion occurring 52
days after the last dose, the pretransfusion sample was 1+
with anticefotetan, and the posttransfusion sample did
not react. No mixed-field reactivity was seen after any
transfusion, including four cases where the pretransfusion
reactivity was 3+ or greater.
We also performed in-vitro studies in an effort to
determine which membrane proteins might be involved
and the minimum concentration for cefotetan binding to





mol/L (Fig. 3). Pretreatment of RBCs with ficin
or DTT did not alter cefotetan binding (minimum posi-





caused a slight diminution in agglutination strength








These data indicate that cefotetan readily becomes tightly
bound to RBCs when administered at prophylactic or
therapeutic doses. After an intravenous dose of 1 g, the









 This is well in excess of the minimal con-




mol/L we found for in-vitro RBC binding.
Cefotetan appears to remain bound to RBCs for most, if
not all, of the life span of the cell. This markedly prolonged
persistence may account for observed hemolytic reactions
that continue for weeks after the drug is withdrawn.
In addition, we found that 5 of 60 patients (8%)  in this
study produced detectable anticefotetan. Although these
patients had at most mild hemolysis, and none had a clin-
ical reaction, this is a strikingly high rate of immune
response. To our knowledge, this is the first study to pro-
spectively identify immune responses to cefotetan. If
further investigations confirm a high rate of antibody
production, then testing previously exposed patients
before administration of cefotetan again may be
warranted.
We did not observe a dual cell pop-
ulation in patients who were transfused
after the last dose of cefotetan. It is
possible that our method was not
sufficiently sensitive to detect a minor
population of RBC that did not react
with anticefotetan. Alternatively, it may
be possible that transfused RBCs
acquired cefotetan from previously
coated cells in vivo. Further studies with
highly sensitive methods such as flow
cytometry will be necessary to distin-
guish between these possibilities.
The mechanism of cefotetan bind-
ing to the RBC membrane is unclear.
Membrane proteins sensitive to ficin
degradation, sialic acid residues, sulfhy-
dryls, and free amines are not likely to
be involved. A slight difference between
untreated and sialydase-treated RBCs






Time from last positive to first negative sample. Results 
for the 15 patients in whom cefotetan testing became negative 
during follow-up. The bottom of each bar indicates that time 
from the last drug dose that the last positive test occurred. The 
top of each bar indicates the occurrence of the first negative 






















Fig. 3. In-vitro treatment of RBCs with cefotetan. RBC-coating by cefotetan at varying 
concentrations of drug. Results are given as the median agglutination strength of three 
replications using four different normal donor RBCs. Pretreatment of RBCs with 
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ance of cefotetan binding is clearly not dependent on
sialic acid.
We conclude from these data that cefotetan binds
tightly to RBCs of patients given typical doses and that the
drug persists on RBCs for about 9 weeks. Furthermore, the
incidence of antibody production to cefotetan may be as
high as 8 percent. Given the common use of cefotetan,
there may be a substantial number of patients at risk of
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